Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis by Satoshi Yamashita & Yukio Ando
Translational 
Neurodegeneration
Yamashita and Ando Translational Neurodegeneration  (2015) 4:13 
DOI 10.1186/s40035-015-0036-yREVIEW Open AccessGenotype-phenotype relationship in
hereditary amyotrophic lateral sclerosis
Satoshi Yamashita* and Yukio AndoAbstract
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease. It is characterized by
neuronal loss and degeneration of the upper motor neurons (UMNs) and lower motor neurons (LMNs), and is
usually fatal due to respiratory failure within 3–5 years of onset. Although approximately 5–10 % of patients with
ALS have an inherited form of the disease, the distinction between hereditary and apparently sporadic ALS (SALS)
seems to be artificial. Thus, genetic factors play a role in all types of ALS, to a greater or lesser extent. During the
decade of upheaval, the evolution of molecular genetics technology has rapidly advanced our genetic knowledge
about the causes of ALS, and the relationship between the genetic subtypes and clinical phenotype. In this review,
we will focus on the possible genotype-phenotype correlation in hereditary ALS. Uncovering the identity of the
genetic factors in ALS will not only improve the accuracy of ALS diagnosis, but may also provide new approaches
for preventing and treating the disease.
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Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neuron disease. It is characterized by
progressive neuronal loss and degeneration of the upper
motor neurons (UMNs) and lower motor neurons
(LMNs). The demise of motor neurons causes the cen-
tral nervous system (CNS) to lose the ability to control
voluntary muscle movement, eventually resulting in
death due to respiratory failure in the later stages of
the disease.
The cause of ALS remains an enigma. However, approxi-
mately 5–10 % of patients with ALS have an inherited form
of the disease. During the decade of upheaval, the evolution
of molecular genetics technology has rapidly advanced our
knowledge about the genetic causes of ALS. Familial ALS
(FALS) has been attributed to mutations in at least 24
different genes. Some mutations in FALS-related genes
have been identified in patients with sporadic ALS (SALS).
Because the initial symptoms of ALS vary across patients, a
diagnosis of ALS can be established by excluding various
diseases mimicking ALS. Smooth and reliable diagnosis is
the first step in the good clinical management of patients* Correspondence: y-stsh@kumamoto-u.ac.jp
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creativecommons.org/publicdomain/zero/1.0/with ALS. Therefore, genetic testing might be a helpful tool
for diagnosing FALS as well as SALS with mutations in
FALS-related genes.
It is important, but difficult, to predict which genes are
most likely to be implicated in some patients with ALS. A
diagnostic algorithm could improve the accuracy of a gen-
etic explanation. Therefore, we review the possible
genotype-phenotype relationship in ALS cases with muta-
tions in the FALS-related genes. Uncovering the identity
of the genetic factors in ALS will not only improve the ac-
curacy of ALS diagnosis, but may also provide new ap-
proaches for preventing and treating the disorder.Classification of hereditary ALS
Hereditary ALS can be transmitted as a dominant,
recessive, or X-linked trait, but the most common type
is an adult-onset disorder with autosomal dominant
transmission. Autosomal recessive inheritance is rarer
and frequently seen in patients with juvenile onset ALS,
primary lateral sclerosis (PLS), or spastic paraplegia-like
symptoms. X-linked dominantly inherited ALS is a
rarely-observed condition, seen in families where male
patients tend to show more severe phenotypes. We dem-
onstrate the characteristic phenotypes in each type of
FALS, and summarize them in Table 1.Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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Table 1 The genotype and phenotype associated with familial ALS-related genes
Type Gene Mode of
inheritance









ALS1 SOD1 AD, AR, de
novo
Japan, Italy, Spain, Korea, UK, USA,
Turkey, Sweden, Iran, Porland, Bulgaria,
China, France, Germany, Denmark,
Pakistan, Canada, and so on
6–94 48 LL > UL > bulbar Positive (LMN
dominant)
Very rare Progressive muscular atrophy, progressive
bulbar palsy, facial onset sensory motor
neuronopathy (FOSMN) syndrome, vocal
cord paralysis, cerebellar ataxia, sensory
disturbance (vibration), autonomic
dysfunction (incontinence, neurogenic
bladder), lower back pain
ALS2 Alsin AR Tunisia, Saudi Arabia, Kuwait, Italy,
Algeria, Hungary, Germany, The
Netherlands, Pakistan, Bangladesh,
Turkey, Japan, Portugal, France,
Cyprus, China
1–11 2 LL, UL Positive None Juvenile ALS, juvenile primary lateral
sclerosis, infantile-onset ascending hereditary
spastic paraplegia, generalized dystonia,
cerebellar ataxia
ALS3 unknown AD
ALS4 SETX AD USA, Austria, Belgium, Italy,
Afghanistan, China
1–73 19 LL > UL Positive None Cerebellar ataxia, oculomotor apraxia (type 2),
motor neuropathy, thin cervical spinal cord
ALS5 SPG11 AR Italy, Turkey, Japan, Canada, Brazil 7–23 16 Bulbar, LL, UL Positive Rare (mental
retardation)
Juvenile ALS, hereditary spastic paraparesis,
autonomic dysfunction (incontinence)
ALS6 FUS AD, AR, de
novo
Belgium, Italy, Korea, UK, Japan,
Turkey, Canada, France, USA,
Germany




Progressive muscular atrophy, Parkinsonism,
essential tremor, schizofrenia, learning
disabilities
ALS7 unknown AD
ALS8 VAPB AD Brazil, UK, France (Japan), The
Netherlands
18–73 44 UL, LL Negative None Progressive muscular atrophy, progressive
bulbar palsy, motor neuropathy, postural
tremor, autonomic dysfunction (chronic
intestinal constipation, sexual dysfunction)
ALS9 ANG AD The Neitherland, Ireland, Scotland,
UK, USA, Sweden, Italy, France,
Germany, China,
21–86 55 UL, LL, bulbar Positive FTD Parkinsonism, progressive bulbar palsy
ALS10 TDP-43 AD, AR Italy, France, UK, China, Germany,
Turkey, USA, Belgium, Japan, Porland,
Afghaistan, Canada
20–77 54 UL, LL, bulbar Positive FTD (rare) Parkinsonism, chorea, progressive
supranuclear palsy
ALS11 FIG4 AD USA 29–77 55 Bulbar > UL, LL Positive None Hereditary spastic paraparesis, primary lateral
sclerosis, personality change
ALS12 OPTN AD, AR Japan, Italy, Turkey, The Netherlands,
Denmark
24–83 51 Bulbar, UL, LL Positive FTD, AGD Primary open angle glaucoma, parkinsonism,
finger deformity, personality change,
depression
ALS13 ATXN2 AD USA, Belgium, the Netherlands,
Canada, France, China, Germany,
Switzerland, Italy, Turkey, Cuba
21–87 60 UL, LL Positive None Cerebellar ataxia, corticobasal syndrome,
Parkinsonism













Table 1 The genotype and phenotype associated with familial ALS-related genes (Continued)




44 UL, LL, bulbar Positive FTD Primary lateral sclerosis, progressive bulbar
palsy, relentlessly progressive
choreoathetoid movements, spastic paralysis
ALS16 SIGMAR1 AD Saudi Arabia 1-68 1 LL > UL Positive FTD (rare) Juvenile ALS




FTD Progressive muscular atrophy, parkinsonism
ALS18 PFN1 AD Sephardic Jewish, Italy, USA, China,
Belgium
33-63 53 Limb N/A N/A
ALS19 ERBB4 AD Japan, Canada 45-70 61 UL, bulbar,
respiration
Positive None
ALS20 HNRNPA1 AD N/A N/A N/A N/A N/A FTD Paget’s Disease, inclusion body myopathy
ALS21 MATR3 AD USA,UK, Italy, Taiwan 36-64 52 LL > UL, bulbar Positive FTD Distal myopathy (inclusion body myopathy)




27–80 57 UL, LL, bulbar Positive FTD Parkinsonism, cerebellar ataxia, psychosis,
ALS-FTD2 CHCHD10 AD France, USA, Germany, Spain, Italy,
Finland
35-73 56 Bulbar, UL, LL Positive (LMN
dominant)
FTD Cerebellar ataxia, mitochondrial myopathy,




Sweden, Denmark, Germany, France,
Portugal
35-80 60 Bulbar, UL, LL,
respiratory
Positive FTD (50 %)
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In 1991, Siddique et al. [1] showed the linkage of FALS
to chromosome 21q by positional cloning and demon-
strated genetic locus heterogeneity in FALS. Rosen et al.
[2] then reported a genetic linkage between FALS and a
gene encoding cytosolic Cu/Zn superoxide dismutase
(SOD1)—a homodimeric metalloenzyme that catalyzes
the reaction of toxic superoxide anion O2
− to O2 and
H2O2. Since SOD1 missense mutations were established
as the first causative genes for ALS, the number of
known mutations has increased to more than 185 so far
(Additional file 1: Table S1). Most cases were inherited
in an autosomal dominant manner, but the D90A
mutation transmitted the disease in both an autosomal
dominant and autosomal recessive manner. Globally,
the most frequent SOD1 gene mutation is D90A.
However, in the USA, the most frequent mutation was
A4V, and in the UK and Japan, the most common mu-
tations were I113T, and H46R, respectively. However,
to our knowledge, no SOD1 mutation was reported
from Ireland. Regarding clinical features of ALS with
the SOD1 mutation, lower limb-onset and predominant
LMN involvement are relatively common (Table 1). The
D90A-homozygous mutation is associated with slowly
progressive paresis in the legs that gradually spreads up to
the arms, thoracic and bulbar musculature, with atypical
non-motor features such as ataxia, neuralgic, aching pain,
heat sensations, and bladder disturbance. Interestingly, it
has been reported that patients with SOD1-related FALS
greatly differed with respect to the age of onset of weak-
ness, while the duration of the disease appears to be char-
acteristic for each type of mutation. Some SOD1 mutants
(D90A-homozygous, E100K, E100G, A89V, L84F, L84V,
D76V, H46R, G37R, and G10V) tend to show a uniform
phenotype, while other mutants (A4V, C6G, G41S, N86S,
D90A-heterozygous, I112M, I113T, L144F, and V148I) have
greatly variable phenotypes. The A4V, H43R, L84V, G85R,
N86S, and G93A mutations have been associated with
rapid disease progression and survival times shorter than
3 years, whereas the cases with G93C, D90A, or H46R mu-
tations exhibit longer life expectancies, up to more than
10 years after disease onset [3–5]. These findings suggest
that each type of SOD1 mutation may be associated with a
different degree of toxicity. We examined two unrelated
FALS families with H46R mutations (Fig. 1). The patients
showed a uniform phenotype: the initial symptom was uni-
lateral weakness of the flexor muscles in the distal lower
limbs (Fig. 1) [6]. This might be attributed to mitochondrial
respiratory chain dysfunction due to mutant SOD1 expres-
sion in the muscles as previously reported [7].
ALS2: Alsin
To date, more than 50 patients with mutations in the
Alsin gene have been reported with early onset of thedisease (~1 year). These patients generally belong to
Middle Eastern, European, and Mediterranean countries,
Japan, and China (Additional file 1: Table S1). All
patients with ALS2 had homozygous or compound het-
erozygous mutations in the Alsin gene. Mutations in the
Alsin gene cause three distinct disorders: infantile as-
cending hereditary spastic paraplegia (IAHSP), juvenile
primary lateral sclerosis (JPLS), and autosomal recessive
juvenile amyotrophic lateral sclerosis (JALS) (Table 1)
[8, 9]. A recent study reported patients with ALS2 with
nonsense and frameshift mutations in the Alsin gene
who presented with generalized dystonia and cerebellar
signs [10]. Although the phenotype-genotype correlation
remains undetermined so far, most of the mutations
predict truncated proteins, which could be unstable in
structure and lose their function.
ALS4: Senataxin (SETX)
Senataxin (SETX) was initially identified as a causative
gene for severe early-onset ataxia with oculomotor
apraxia (AOA2), which is the second most common re-
cessive ataxia after Freidreich's ataxia [11]. Later, hetero-
zygous mutations were found in patients with the
autosomal dominant form of juvenile-onset ALS [12].
ALS4 is characterized by slowly progressive distal
muscle weakness and atrophy with pyramidal signs,
sparing of bulbar and respiratory muscles, and frontal
dysfunction (Table 1) [13]. So far, the T3I, L389S,
T1118I, C1554G, K2018E, K2029E, R2136H, and I2547T
mutations in the SETX gene have been identified in both
patients with FALS and those with SALS with widely
differing symptoms (Additional file 1: Table S1). In a
recent report, a patient with late onset ALS4, bulbar
involvement, and predominantly proximal distribution
of amyotrophy presented with choreic movements and
elevated alpha-fetoprotein levels [14]. In contrast, one
study demonstrated that previously published ALS4-related
missense mutations are most likely to be non-pathogenic
and just polymorphisms [15]. Therefore, we should care-
fully interpret the significance of SETX missense mutations
in the absence of functional assays.
ALS5: Spastic paraplegia 11, autosomal recessive (SPG11)
Mutations in the Spatacsin (SPG11) gene represent the
most common form of autosomal recessive hereditary
spastic paraplegia with thin corpus callosum (HSP-TCC)
[16]. Recently, SPG11 mutations have been identified in
patients with the autosomal recessive form of juvenile
ALS, indicating a wide clinical spectrum for SPG11
mutations [17]. The SPG11 mutations can be associated
with an intrafamilial phenotypic heterogeneity, including
atypical ALS and classic HSP-TCC [18]. To our know-
ledge, at least 28 patients with ALS5 have been
described with juvenile onset of the disease, ranging
Fig. 1 Two FALS families with the SOD1 H46R mutations. a Family trees of Family 1 and 2. All of the patients showed the same uniform feature
that initial symptoms were restricted to the flexor muscle group in the unilateral distal leg. b Short-T1 inversion recovery MR images revealed high
intensity lesions in the gastrocnemial and soleus muscles of the patient 2, 3, 4, and 5. Brain MRI of patient 1 showed frontal lobe-dominant atrophy
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S1). All patients with ALS5 were associated with slow
progression of symptoms with apparent UMN involve-
ment (Table 1). It has been reported that the absence of
thin corpus callosum, white matter alterations, cognitive
deficits or mental problems clearly differentiates ALS5
from HSP-TCC [17]. At this point, it is unclear why the
SPG11 mutations lead to clinical phenotypes resembling
ALS or HSP-TCC.
ALS6: Fused in sarcoma/translocated in liposarcoma
(FUS/TLS)
Two independent studies have reported that mutations
in the fused in sarcoma/translocated in liposarcoma
(FUS/TLS) gene were responsible for ~3 % of FALS and
<1 % of SALS cases [19, 20]. FUS/TLS mutations, as well
as TAR DNA-binding protein (TDP-43) mutations, have
been increasingly reported from Asian countries [21, 22].Some FUS/TLS gene mutations have been observed in
patients with the juvenile form of ALS beginning at youn-
ger than 25 years [23–25, 22]. Case studies with the R521C
mutation in the FUS/TLS gene emphasized the phenotypes
of weakness of the neck and proximal muscles, which may
be a clinical hallmark of ALS [26]. Most of the reported
cases with the FUS/TLS mutation had no cognitive
change. However, some of the patients with juvenile ALS
with truncating FUS/TLS mutations have had mental
retardation [27, 22].
Most ALS-related FUS/TLS mutations are located at
the highly conserved regions of exon 15 that include the
non-canonical nuclear localization signal (PY-NLS).
Recent studies have shown that the mutations that nul-
lify the PY-NLS lead to redistribution of FUS/TLS to
the cytoplasm, where it is recruited into stress granules
[28–30]. Notably, the degree of cytosolic mislocaliza-
tion has been shown to be inversely correlated with the
Yamashita and Ando Translational Neurodegeneration  (2015) 4:13 Page 6 of 13age of disease onset [29]. It has been reported that the
truncating mutation R495X was associated with an
aggressive disease course, whereas the K510R mutation
showed a mild phenotype with disease duration ranging
from 6 to 8 years [31].
ALS8: Vesicle-associated membrane protein-associated
protein B (VAPB)
A mutation in the vesicle-associated membrane protein-
associated protein B (VAPB) gene was initially reported
in Brazilian families with motor neuron disease with a
wide range of phenotypes: late-onset spinal muscular
atrophy, atypical ALS, or typical ALS [32]. In addition,
several patients showed autonomic abnormalities, in-
cluding chronic intestinal constipation, and sexual
dysfunction [33]. So far, the T46I, P56S, and V234I
mutations in the VAPB gene have been described in
patients from Brazil, Japan, the United Kingdom, and
the Netherlands (Additional file 1: Table S1). Further
investigation will be required to understand the
phenotype-genotype correlation.
ALS9: Angiogenin (ANG)
A cohort study in Ireland has identified several mutations
in the angiogenin (ANG) gene in patients with ALS of
Irish and Scottish background, both in familial and spor-
adic cases [34]. Subsequent clinical studies confirmed the
association of these mutations with ALS, and identified
new mutations in people with backgrounds from Brazil,
China, France, Germany, Italy, Netherlands, Sweden, and
the USA (Supplementary Table 1). Frontotemporal de-
mentia (FTD) was also reported in a large FALS pedigree
with the K17I ANG mutation [35]. Moreover, a relation-
ship between mutations in the ANG gene and Parkinson’s
disease has been revealed [36].
ALS10: TAR DNA-binding protein (TDP-43)
Several groups have identified mutations in a highly
conserved region of TDP-43 in SALS and FALS cases
[37–40]. Most mutations are located in exon 6, which
encodes the conservative glycine-rich domain. The
phenotype and genotype analysis study in patients with
ALS having TDP-43 gene mutations revealed that they
had earlier onset (53.4 years; range 28-78), predomin-
antly upper limb onset (60.7 %), and longer disease
duration (63.0 months; range 32.0-77.2), compared with
those having SALS [41]. In Caucasians, 51.3 % of the
patients had the upper limb onset, whereas 58.8 % of
Asian patients had bulbar onset [41].
ALS11: FIG4 homolog, SAC1 lipid phosphatase domain
containing (S. cerevisiae) (FIG4)
Mutations in the FIG4 gene are responsible for the re-
cessive form of Charcot-Marie-Tooth disease (CMT4J),with early onset and involvement of both sensory and
motor neurons [42]. Subsequently, the same group iden-
tified ALS as a rare manifestation of the gene [43]. The
phenotype observed in patients with FIG4 mutations is
still controversial. Some patients carried a diagnosis of
definite or probable ALS, and other patients were diag-
nosed with PLS, associated with predominant UMN
involvement. Personality changes were also reported in
patients with ALS11.
ALS12: Optineurin (OPTN)
Maruyama et al. [44] identified mutations in the
optineurin (OPTN) gene in 3.8 % of Japanese with FALS
and 0.29 % of Japanese with SALS. Mutations in the
OPTN gene were also detected in some patients with
both FALS and SALS in cohorts of Italian, Danish,
French, Turkish, and German patients (Additional file 1:
Table S1). As mentioned later, the role of OPTN in the
pathogenesis of ALS has been further examined in a
recent publication on the TANK-binding kinase (TBK1)
gene [45, 46]. The clinical phenotypes of OPTN-related
ALS showed relatively slow progression and long dur-
ation before respiratory dysfunction, but the onset age of
the eight individuals with mutations of OPTN ranged
from 30 to 60 years [44]. Brain atrophy with personality
change or depression was also observed in patients with
ALS12.
ALS13: ataxin 2 (ATXN2)
Long polyglutamine tracts, including more than 34 CAG
repeats in the ataxin 2 (ATXN2) gene, have been identi-
fied as a cause of spinocerebellar ataxia type 2 (SCA2)
[47]. Recent studies revealed that intermediate-length
polyglutamine repeats (between 24 and 33) within the
ATXN2 gene can be a risk factor for patients with ALS
in different ethnic groups [48–50]. However, whether
the clinical features of patients with ALS can be affected
by ATXN2 intermediate-length repeats is still controver-
sial [49–51].
ALS14: Valosin-containing protein (VCP)
Using exome sequencing, Johnson et al. [52] identified a
R191Q mutation in the valosin-containing protein (VCP)
gene in an Italian family with autosomal dominantly
inherited ALS. Screening of the VCP gene in a cohort of
ALS cases identified several mutations including a patho-
logically proven case of ALS. Mutations in the VCP gene
have previously been identified in families with inclusion
body myopathy, Paget disease, and frontotemporal
dementia (IBMPFD) [53]. The phenotype of patients with
VCP mutations shows intrafamilial variations from
IBMPFD to FALS [54]. This suggests that motor neuron
disease is part of the clinical spectrum of multiple protei-
nopathy of VCP-associated disease.
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Recent studies have revealed that ubiquilin 2 (UBQLN2),
which regulates the degradation of ubiquitinated proteins,
plays a pathogenic role in the X-linked form of ALS with
or without FTD [55]. In an original case, the disease was
transmitted in a dominant fashion with reduced pene-
trance without male-to-male transmission of the disease.
Age at onset was significantly different between male and
female patients, with male patients having earlier age of
onset [55]. Mutations in UBQLN2 are not a frequent
cause of ALS in the Dutch, French-Canadian, French,
Irish, Taiwanese, and Korean population (Additional file 1:
Table S1).
ALS16: σNon-opioid receptor (SIGMAR1)
Homozygosity mapping followed by direct sequencing
has revealed a mutation in the σNon-opioid receptor
(SIGMAR1) gene in patients in a consanguineous family
with the autosomal recessive form of juvenile ALS in
Saudi Arabia [56]. Furthermore, variants in the 3′-un-
translated region (UTR) of the SIGMAR1 gene were
reported in patients with frontotemporal lobar degen-
eration (FTLD) or motor neuron disease with FTLD
[57]. However, the same family with the 3′-UTR muta-
tion of the SIGMAR1 gene also had an expansion of a
noncoding GGGGCC hexanucleotide repeat in the
chromosome 9 open reading frame 72 (C9ORF72)
[58]. This indicates that coding and noncoding vari-
ants located in the 3'-UTR of the SIGMAR1 gene are
not the cause of FTLD-MND.
ALS17: chromatin modifying protein 2B (CHMP2B)
Mutations in the charged multivesicular body protein 2B
(CHMP2B) gene have been initially identified in patients
with FTD [59]. Although the phenotype is predomin-
antly FTD, ALS has been reported as a rare manifest-
ation of the gene [60, 61]. Neuropathology of the patient
with the mutation showed LMN predominant disease
with ubiquitylated inclusions in motor neurons [60].
Thus, classical ALS and PMA without corticospinal find-
ings are phenotypes associated with mutations in the
CHMP2B gene.
ALS18: profilin 1 (PFN1)
Exome sequencing followed by direct sequencing has
shown mutations in the profilin 1 (PFN1) gene, which is
a central regulator of actin dynamics in some FALS
cases [62]. However, cohort analyses of patients with
FALS and those with SALS from France and Quebec,
Italy, Germany, the Nordic countries, and the United
States suggested that the PFN1 mutation is a rare cause
of ALS (Additional file 1: Table S1). In the original
report, all patients with ALS18 showed limb symptoms
at a relatively younger onset [62].ALS19: v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 4 (ERBB4)
A whole-genome sequencing and parametric linkage
analysis identified the mutation in the v-erb-b2 avian
erythroblastic leukemia viral oncogene homolog 4 (ERBB4)
gene in patients of a Japanese family with late-onset,
autosomal-dominant ALS [63]. An extensive mutational
analysis revealed the same mutation in a Canadian individ-
ual with familial ALS and a de novo mutation in a Japanese
case [63]. As of this moment, the genotype-phenotype cor-
relation has not been determined.
ALS20: heterogeneous nuclear ribonucleoprotein A1
(hnRNPA1)
Exome sequencing revealed mutations in the heteroge-
neous nuclear ribonucleoprotein A1 (hnRNPA1) gene
in patients presenting with ALS and/or multisystem
proteinopathy (MSP). These mutations are associated
with a rare and complex phenotype associating FTLD,
Paget disease of bone, and inclusion body myopathy
[64]. Because the clinical information is not fully avail-
able, the phenotype of patients with mutant hnRNPA1
is still unclear.
ALS21: matrin-3 (MATR3)
A recent study using exome sequencing revealed muta-
tions in the matrin-3 (MATR3) gene in FALS and FTD
cases [65]. Initially, the S85C mutation in the MATR3
gene was reported as the cause of autosomal dominant
distal myopathy with vocal cord paralysis (VCPDM) in
large multi-generational families [66]. The phenotype
observed in some patients carrying MATR3 mutations is
still controversial. However, the clinical phenotype might
be markedly similar to that observed in patients with
mutations in VCP, hnRNPA1, and HNRNPA2B1 as MSP.
We examined 2 sisters with VCPDM and S85C mutations
in the MATR3 gene (Fig. 2) [67]. Both patients showed no
UMN symptoms clinically; however, they showed chronic
denervation and renervation on electromyography and
muscle biopsy, split hand syndrome, and decremental
motor responses to repetitive nerve stimulation, suggest-
ing the involvement of LMNs [67].
ALS-FTD1: chromosome 9 open reading frame 72
(C9ORF72)
Two independent studies have discovered an expansion
of a noncoding GGGGCC hexanucleotide repeat in the
C9ORF72 gene that is associated with disease in a large
FTD/ALS kindred linked to chromosome 9p [68, 69].
Analysis of extended clinical series found the C9ORF72
repeat expansion to be the most common genetic abnor-
mality in both familial FTD (11.7 %) and familial ALS
(23.5 %) [68]. Another study reported that the C9ORF72
intronic expansion was present in 11 % of the cohort,
Fig. 2 A family with the MATR3 S85C mutation. a Family tree of cases with the MATR3 S85C mutation. The detailed clinical information was
previously described [67]. b Short-T1 inversion recovery MR images revealed fatty and degenerative changes in the gluteus, quadriceps, and
hamstring muscles of patient 1 and the paraspinal and gluteus muscles of patient 2. c Needle electromyography demonstrated chronic
denervation in the vastus lateralis muscles of patients 1 and 2. d Muscle biopsy from patients 1 and 2 showed severe fatty and myopathic
changes with rimmed vacuoles. Immunohistochemical analysis demonstrated p62- or TDP-43-positive sarcoplasmic granular staining in
degenerating myofibers of patient 1. The observation of chronic denervation and renervation on electromyography and muscle biopsy, split hand
syndrome, and decremental motor responses to repetitive nerve stimulation (data not shown) suggest the involvement of lower motor neurons
in patients 1 and 2
Yamashita and Ando Translational Neurodegeneration  (2015) 4:13 Page 8 of 1343 % of FALS cases, and 7 % of SALS cases [69]. There-
fore, C9ORF72 has been thought to be the most common
cause of ALS in Caucasians, but rarer in other populations
[70]. It is still controversial whether the patients with
C9ORF72 expansion have shorter disease duration and
relatively rapidly progression. C9ORF72 expansion can
also cause parkinsonism and dementia. There is no as-
sociation between the repeat length of the normal al-
leles, of the repeat in C9ORF72, and disease phenotype
or age at onset in C9ORF72 mutation carriers or non
carriers [71].ALS-FTD2: Coiled-coil-helix-coiled-coil-helix domain
containing 10 (CHCHD10)
Whole-exome sequencing identified a missense S59L mu-
tation in the coiled-coil-helix-coiled-coil-helix domain
containing 10 (CHCHD10) gene in a large family with a
late-onset phenotype including motor neuron disease, cog-
nitive decline resembling FTD, cerebellar ataxia and my-
opathy [72]. Multiple mitochondrial DNA deletions have
been found in the skeletal muscles of patients with ALS-
FTD2, suggesting mitochondrial DNA instability. Thus,
the phenotype can vary according to affected organs.
Yamashita and Ando Translational Neurodegeneration  (2015) 4:13 Page 9 of 13TANK-binding kinase 1 (TBK1)
Recently, several studies using exome sequencing of mod-
erate numbers of patients with ALS identified the TBK1
gene as an ALS gene, which is known to bind to and phos-
phorylate ALS-related proteins such as OPTN and p62
(SQSTM1/sequestosome) [45, 46]. Patients having ALS
with the mutations frequently (~50 %) showed cognitive
impairment [46]. Another study performing whole-
genome sequencing in patients with FTLD-TDP found
variants in the TBK1 gene, indicating a key role for the
OPTN/TBK1 pathway in ALS and FTD [73].
Importance of genetic testing for ALS diagnosis
We describe the possible correlation between the
genotype and phenotype, and aim to provide a clue to
the diagnosis of ALS. ALS cases can be divided into 3
groups: juvenile onset less than 10 years or less
25 years, and adult onset type. Cases with juvenile
onset were categorized into 2 groups because we could
differentiate the genes that cause juvenile ALS alone
from the genes that cause both juvenile and adult-
onset ALS. ALS cases with juvenile onset less than
10 years include cases with mutations in the SPG11,
Alsin, SETX, and SIGMAR1 genes (Fig. 3). When the
symptoms are UMN-dominant, SPG and Alsin can be
causative genes for ALS. In contrast, SETX might be
responsible in cases with LMN-dominant symptoms
such as PMA type. In ALS cases with onset from 10 to
24 years, SPG11, FUS, VAPB, SOD1, SETX, ATXN2,
ANG, and UBQLN2 should be considered as a cause
of ALS (Fig. 3). SPG or UBQLN2 might be a causative
gene in UMN-dominant cases whereas FUS, VAPB,
SOD1, and SETX should be examined in LMN-
dominant cases.
In adult-onset ALS cases, many candidate genes
should be excluded (Fig. 4). In patients who suffer
from mental retardation, SPG11 may be responsible in
UMN-dominant cases and FUS may be responsible in
LMN-dominant cases. Coexistence with cerebellar
ataxia may suggest the involvement of mutations of
SOD1, ATXN2, Alsin, and SETX. Complications of
motor neuropathy might occur in cases with mutations in
the FIG4, SETX, VAPB, and SOD1 (homozygous D90A)
genes. FTD can be present in cases with mutations in the
UBQLN2, SIGMAR1, TDP-43, ANG, OPTN, CHMP2B,
and C9ORF72 genes. Moreover, parkinsonism can be in-
volved in cases with TDP-43, ANG, OPTN, and CHMP2B
mutations. In some cases, muscle biopsy provides useful
information for ALS diagnosis. Mitochondrial myopathy
is reported in cases with CHCHD10 and SOD1 muta-
tions (Fig. 1). FTD in combination with inclusion body
myopathy and Paget’s disease of bone in the patients
or families strongly suggests mutations in the VCP,
hnRNPA1, or MATR3 genes (Fig. 2).Although these algorithms might provide some indica-
tions of what type of genetic abnormality might be present
in a large enough family with somewhat consistent features,
most families have a small number of affected individuals
with wide variability. Thus, these algorithms may be inef-
fective. However, ethnic background plays a huge role in
determining which genes are most likely. The proportion of
ALS caused by a particular gene in a particular population
can be a stronger predictor: C9ORF72 intronic expansion is
very common in Caucasians, but rare in other populations.
Therefore, the algorithms should be optimized based on
ethnic backgrounds, and establishment of panels that
examine all genes simultaneously would be ideal.
Another limitation is that phenotypes were described
in limited number of patients in some genes except
SOD1, FUS/TLS, TDP-43, and C9ORF72. This makes it
is difficult to draw conclusive genotype-phenotype corre-
lations. Moreover, some of the reported mutations were
not necessarily pathogenic, just polymorphisms [15]. Thus,
it is difficult to know which reported variants indeed cause
the disease; it even more difficult in cases having oligogenic
inheritance because their phenotype is derived from the
combination of two genes.
Notably, half of the families with FALS do not have a
mutation in the identified genes and therefore the
genetic test is not necessarily informative for all cases of
FALS. At this point, the determination that an individual
has FALS is based on a family history rather than a
genetic test. If one's family history is unknown or a par-
ent passed away at a young age, testing is appropriate.
Those patients with SALS without a family history can
also be offered genetic testing. However, it is extremely
important that this be done in the context of genetic
counseling or after discussion with a neurologist about
the implication of finding a mutation, as a mutation
would mean that the ALS is hereditary. Although
prenatal genetic testing technology exists, the patients
and family members should discuss the procedure with
their neurologist and genetic counselor for further infor-
mation on this complex and personal matter [74].
Conclusions
There is no specific test or procedure to establish the
diagnosis of ALS. A diagnosis of ALS can be established
by ruling out other diseases that mimic ALS thorough
comprehensive diagnostic examinations. Earlier diagno-
sis allows prompt initiation with a specific drug, such
as riluzole, and accurate palliative care planning. The
recent advances in the genetics of ALS have not only
contributed to our understanding of the pathogenesis
of ALS, but have also provided a tool for diagnostic
procedures in some cases of ALS.
Despite all the progress achieved, the large majority of
ALS genes remain unknown. The number of genes
Fig. 4 Flowchart for diagnosis of hereditary adult-onset ALS
Fig. 3 Flowchart for diagnosis of hereditary juvenile-onset ALS
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ously increase with the evolution of molecular genetics
technology. Further discovery of the genetic factors in
ALS will contribute considerably to the diagnosis, care,
prevention, and treatment of ALS.
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